Compare · ALZN vs NVO
ALZN vs NVO
Side-by-side comparison of Alzamend Neuro Inc. (ALZN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALZN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 28114.9x ALZN ($6.2M).
- Over the past year, ALZN is down 43.0% and NVO is down 28.6% - NVO leads by 14.4 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 2 for ALZN).
- NVO has more recent analyst coverage (25 ratings vs 1 for ALZN).
- Company
- Alzamend Neuro Inc.
- Novo Nordisk A/S
- Price
- $1.34-1.47%
- $38.82-1.05%
- Market cap
- $6.2M
- $173.66B
- 1M return
- -26.98%
- -10.14%
- 1Y return
- -42.98%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 4
- Recent ratings
- 1
- 25
Alzamend Neuro Inc.
Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ALZN
- SEC Form RW filed by Alzamend Neuro Inc.
- Alzamend Neuro Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
- SEC Form 10-Q filed by Alzamend Neuro Inc.
- Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)
- Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)
- Director Ault Milton C Iii sold $3,116 worth of shares (2,000 units at $1.56), closing all direct ownership in the company (SEC Form 4)
- SEC Form PRE 14A filed by Alzamend Neuro Inc.
- SEC Form S-1 filed by Alzamend Neuro Inc.
- Amendment: SEC Form 4 filed by Director by deputization Hyperscale Data, Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank